**Title:** Piyush Goyal Critiques Incremental Patent Strategies in Pharma
**Meta Description:** Commerce Minister Piyush Goyal condemns incremental patenting in pharmaceuticals, emphasizing the need for affordable healthcare access.
**URL Slug:** piyush-goyal-pharma-patent-critique
**Headline:** Piyush Goyal Criticizes Incremental Innovations in Pharmaceutical Patents
In a recent address, Commerce and Industry Minister Piyush Goyal expressed strong disapproval of certain pharmaceutical companies’ attempts to secure patents through minor incremental innovations. He highlighted that such practices could hinder access to affordable medicines for millions, all for the sake of maximizing profits for a select few companies and their shareholders.
Goyal noted that he frequently receives requests to permit pharmaceutical firms to make incremental changes to their patents, which would allow them to obtain new patents for extended periods. This practice, often referred to as “evergreening,” is seen as a way for companies to extend their monopoly on drugs just as their original patents are nearing expiration. “It is disheartening that the pursuit of profit for a handful of companies results in widespread suffering and a lack of quality healthcare for many,” he stated during the event.
Under Section 3(d) of the Indian Patents Act, 1970, patents for already-known drugs are restricted unless the new claims demonstrate superior efficacy. Additionally, Section 3(b) prohibits patents for products that do not serve the public interest or show enhanced efficacy over existing options. Despite this, some multinational corporations have urged India to amend these laws, a move that has faced significant opposition.
The strategy of evergreening involves making minor modifications, such as altering formulations or adding new mixtures, to renew patent rights. This approach can grant companies a 20-year monopoly on the modified drug, further complicating access to affordable medications.
Goyal emphasized that access to quality healthcare is essential for sustainable development and shared insights into India’s progress in improving healthcare access for all citizens.
In conclusion, the ongoing debate over pharmaceutical patenting practices raises critical questions about the balance between innovation and public health. As the global community grapples with these issues, the need for equitable healthcare access remains paramount.
**FAQ Section:**
**Q: What is evergreening in pharmaceutical patents?**
A: Evergreening refers to the practice of making minor changes to existing drugs to extend patent protection, allowing companies to maintain monopolies and potentially limit access to affordable medications.
